Compare PGEN & HYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGEN | HYI |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 272.7M |
| IPO Year | N/A | N/A |
| Metric | PGEN | HYI |
|---|---|---|
| Price | $4.37 | $11.02 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.67 | N/A |
| AVG Volume (30 Days) | ★ 4.7M | 50.6K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.59% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,309,000.00 | N/A |
| Revenue This Year | $342.78 | N/A |
| Revenue Next Year | $478.46 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 59.20 | N/A |
| 52 Week Low | $0.69 | $10.99 |
| 52 Week High | $5.23 | $12.24 |
| Indicator | PGEN | HYI |
|---|---|---|
| Relative Strength Index (RSI) | 64.73 | 38.79 |
| Support Level | $3.64 | $11.00 |
| Resistance Level | $3.75 | $11.06 |
| Average True Range (ATR) | 0.26 | 0.06 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 91.40 | 11.11 |
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. The fund invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.